Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). (Q38101883)

28 August 2017

title

Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). (English)

1 reference

28 August 2017

1 reference

Rashmi R Shah

1

1 reference

28 August 2017

Joel Morganroth

series ordinal

2

1 reference

28 August 2017

Devron R Shah

series ordinal

3

1 reference

28 August 2017

publication date

1 May 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

36

1 reference

28 August 2017

issue

5

1 reference

28 August 2017

page(s)

295-316

1 reference

Cardiovascular toxicity of molecularly targeted agents.

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Cardiovascular toxicity of anti-angiogenic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

The significance of QT interval in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Cardiac repolarisation and drug regulation: assessing cardiac safety 10 years after the CPMP guidance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Drug-induced QT interval prolongation: does ethnicity of the thorough QT study population matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Molecularly targeted oncology therapeutics and prolongation of the QT interval

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

QT interval prolongation among patients treated with angiogenesis inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Cardiotoxicity of tyrosine-kinase-targeting drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Targeting cancer with small molecule kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Tyrosine kinase inhibitors of VEGF receptors: clinical issues and remaining questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Gastrointestinal toxicities of novel agents in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Suppression of phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long QT syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

A fresh perspective on comparing the FDA and the CHMP/EMA: approval of antineoplastic tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

hERG K(+) channels: structure, function, and clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Assessing proarrhythmic potential of drugs when optimal studies are infeasible.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Early investigation of QTc liability: the role of multiple ascending dose (MAD) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Blocking of the human ether-à-go-go-related gene channel by imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Evaluation of cardiac safety of lapatinib therapy for ErbB2-positive metastatic breast cancer: a single center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Clinical cardiac safety profile of nilotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Modulation of human erg K+ channel gating by activation of a G protein-coupled receptor and protein kinase C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Deletion of protein kinase A phosphorylation sites in the HERG potassium channel inhibits activation shift by protein kinase A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

HERG potassium channel activation is shifted by phorbol esters via protein kinase A-dependent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Requirement of a macromolecular signaling complex for beta adrenergic receptor modulation of the KCNQ1-KCNE1 potassium channel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

PKA phosphorylation of HERG protein regulates the rate of channel synthesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Protein kinase A activity at the endoplasmic reticulum surface is responsible for augmentation of human ether-a-go-go-related gene product (HERG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Mechanisms underlying the protein-kinase mediated regulation of the HERG potassium channel synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Normal function of HERG K+ channels expressed in HEK293 cells requires basal protein kinase B activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Both EGFR kinase and Src-related tyrosine kinases regulate human ether-à-go-go-related gene potassium channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

QTc shortening with a new investigational cancer drug: a brief case study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Effects of fluorine substitution on drug metabolism: pharmacological and toxicological implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Metabolism of fluorine-containing drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Thrombosis associated with angiogenesis inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Cardiovascular side-effects of modern cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Cardiotoxicity associated with targeting kinase pathways in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Hypertension as a surrogate marker for the activity of anti-VEGF agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Mechanisms of hypertension associated with BAY 43-9006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Key roles of Src family tyrosine kinases in the integrity of the pulmonary vascular bed.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Role of Src tyrosine kinases in experimental pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Reversal of experimental pulmonary hypertension by PDGF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Imatinib for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Portopulmonary hypertension: imatinib as a novel treatment and the Emory experience with this condition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Evaluation of imatinib mesylate in the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Imatinib mesylate for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Targeting PDGF pathway in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Imatinib mesylate has the potential to exert its efficacy by down-regulating the plasma concentration of platelet-derived growth factor in patients with pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

A novel murine model of severe pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Imatinib attenuates hypoxia-induced pulmonary arterial hypertension pathology via reduction in 5-hydroxytryptamine through inhibition of tryptophan hydroxylase 1 expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Effects of multikinase inhibitors on pressure overload-induced right ventricular remodeling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

The compelling need for a cardiology and oncology partnership and the birth of the International CardiOncology Society.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Why do kinase inhibitors cause cardiotoxicity and what can be done about it?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Cardiovascular toxicity associated with small molecule tyrosine kinase inhibitors currently in clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Mechanisms of myocyte cytotoxicity induced by the multikinase inhibitor sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Cardiovascular toxicity profiles of vascular-disrupting agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Cardiotoxicity of the new cancer therapeutics--mechanisms of, and approaches to, the problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Tyrosine kinase inhibitor (TKI)-induced cardiotoxicity: approaches to narrow the gaps between preclinical safety evaluation and clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

PDGF-B signaling is important for murine cardiac development: Its role in developing atrioventricular valves, coronaries, and cardiac innervation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0047-5

[Torsades de pointe. Apropos of 60 cases]

21 January 2018

1 reference

12 December 2020

Mitochondria death/survival signaling pathways in cardiotoxicity induced by anthracyclines and anticancer-targeted therapies

1 reference

12 December 2020

Tyrosine kinases as targets for cancer therapy

1 reference

12 December 2020

Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysis

1 reference

12 December 2020

Introduction to cardiotoxicity review series

1 reference

12 December 2020

Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma

1 reference

12 December 2020

Baseline heart rate-corrected QT and eligibility for clinical trials in oncology

1 reference

12 December 2020

Regulation of ion channels by protein tyrosine phosphorylation

1 reference

12 December 2020

Evaluation and management of cardiac safety using the electrocardiogram in oncology clinical trials: focus on cardiac repolarization (QTc interval)

1 reference

12 December 2020

[Torsade de pointes. Apropos of 54 cases]

1 reference

12 December 2020

Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials

1 reference

12 December 2020

An overview of class III electrophysiological agents: a new generation of antiarrhythmic therapy

1 reference

12 December 2020

Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs

1 reference

12 December 2020

10.1007/S40264-013-0047-5

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1046942550

0 references

1 reference